Our expensive obesity drugs are worth it, Novo Nordisk and Eli Lilly argue in raft of studies; It’s time for the FDA to halt Cassava Sciences’ Alzheimer’s clinical trials

Taking stock of the drug industry, from the lab to the medicine chest

October 17, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Elaine Chen STAT+ | Our expensive obesity drugs are worth it, Novo Nordisk and Eli Lilly argue in raft of studies Yet many of the studies, being presented at ObesityWeek, don't include the considerable cost of obesity drugs like Ozempic and Mounjaro. By Elaine Chen STAT+ | It's time for the FDA to halt Cassava Sciences' Alzheimer's clinical trials Some thoughts on the fallout from the CUNY investigation that raised serious doubts about the experimental drug simufilam. By Adam Feuerstein STAT+ | When Medicare paid doctors differently, fewer patients had heart problems Doctors lowered the incidence of heart disease and strokes among their patients when Medicare rewarded them for focusing on sicker patients. By John Wilkerson Illustration: Christine Kao/STAT; Courtesy: Lotte Bjerre Knudsen STAT+ | How one scientist's determination made Novo Nordisk an obesity-drug powerhouse "It was only Lotte's enthusiasm that made it at all possible to get anywhere," said one of Knudsen's scientific collaborators. By Megan Molteni

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser